Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Joya Griffin, DVM, DACVD, shared her love of ‘extreme makeovers’ for patients in a keynote address at Fetch Charlotte.
Joya Griffin, DVM, DACVD, discusses the concept of ‘food as medicine’ and how prescription diets can help restore the skin’s ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...
Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis fungoides.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback